(Reuters) - Perrigo Co (NYSE:PRGO) Plc said on Monday that the U.S. Food and Drug Administration had scheduled a meeting of external experts on Nov. 18 to review the application of its daily birth control pill for over-the-counter (OTC) use.
Continue reading your article with a FrontPage News Subscription
Already a Subscriber? Sign In
VIEW SUBSCRIPTION OPTIONS
Support independent journalism by subscribing